In recent years, the neurodegenerative diagnosis and treating many diseases up to a few years have experienced great improvements Multipple sclerosis. One of the new tools that contribute to improve the attitude of these diseases is new biomarks, not only to detect, but also help to measure the course of the disease.
In recent years it has been increasingly appropriate Light in serum chain neuroflaments (SNFLS) That, as he revealed Neurosamit 2025, 168 experts from all over Spain attended, which is becoming the most effective tool to measure the course Multiple sclerosis (EM) and optical neuromilitis (NMO) It is believed that this is applicable to many diseases that cause neurological damage, that is Dr. Louisa Maria Willer CuimersPresident of the Raman Y Kajal University Hospital in Madrid.
What is neuroflaments and what is measured with them
When there is a Neurological damage. Cytosclaton. Cytosclaton destroys, and other things, when one of the neuroflaments, which is part of that structure, breaks an act. “
From about 10 or 15 years, a series of people, including Louisa Maria Willer Guemarans, began to work about it, and when neuroflaments were increased in the cerebrospinal fluid, this is the central nervous system that is bathing in the central nervous system. Damage to molds. Then, when high sensitivity methods appeared, they were able to detect in low activities, but at the same rate, Neuroflamentes. They also felt that the damage could be detected before the patient had high symptoms, “It is predicted to have an increase in these blood molecules, and that inflammation, like the multiple sclerosis, causes damage to the molds. When a treatment begins, it does not cause inflammation,” he explains, “he explains.
The increase in these neuroflaments in the blood is predicted that inflammation can cause damage to the Axons, just like multiple sclerosis
The use of this marker today has been proven to be effective, above all, Monitor treatments, That is, it is known whether they work or not they work before the patient explodes and creates a disability, which is unchanged in the case of Sclerus Multiple. It is a Almost aggressive method because it is a simple blood analysisHe explains, “Panchar is done at the beginning of measuring neuroflaments, to detect the amount of damage and to know whether the amount of damage is lost, but it does not help you to monitor the treatments, because you cannot do pelvic panches every small patient, and once a year.” “
However, through blood analysis, the treatment can be monitored Each time when the expert is requiredAnd if he noticed that he creates neurological damage by inflammation and changes the treatment, “It helps to measure this Choose one treatment or another depending on whether the patient is suffering from damage High axis. Monitor the patient and see how it works, and when you have already chosen treatment. If it works, you will leave it, but if you look at high neurological damage, you can progress than the clinic, before the patient is observed at the body level or the explosion, and you will find it before the patient worsens. You can expect to have a patient Disability. ”
In the case NeurosisEM or NMO is very important because there are available treatments and are supplied in explosives, causing the inability to accumulate. Avoiding an explosion, long -term, inability, or delaying, “this biomarker allows for severe inflammation, because when there is severe damage, the neuroflaments will increase,” he explains.
Before the patient takes care of it or erupts, it can be detected if there is too much neurological damage, before the worsening
Only the tip of the iceberg
The Neuroflament measurement It is used every time in the attitude of Multiple Sclerosis, but the purpose of researchers like Dr. Louisa Maria Willer Guemarans is that “this is not done now, but it extends to how effective its use is. Further activated in clinical practice ”He explains.
In the future you do not reject that you can use some events, but additional studies need, “The diagnosis has other tests, but in some cases I know I can use in the future. For example, in health centers, a patient is suspicious. Doing this test may bring those doubts close to Send the specialist to the patient quickly, but this is examined, which is not included in the last diagnostic criteria because we have no enough resources yet, ”he admits.
Several studies are missing, but it is very sure if Dr. Louisa Maria Willer has any This biomarker will give you more to speak In the coming years, not only in these two diseases, but also “neuroflaments talk about print damage, and not just molding damage to multiple sclerosis and optical neuromelitis. We have clear data in these diseases, but now they operate in other syndromes like them. SheOvarian ParkinsonOvarian Alcellus… There, along with other proteins studied in both the seribrosphenular fluid and serum, we believe Evaluate the follow -up and see how the patients are formed and they help us. We are confident that multiple sclerosis is only the tip of the glacier and that it will soon be used in other neurological syndromes, ”he says.
This iceberg may even go Beyond neurological illnessesDiseases too This causes damage to the central nervous system.There is nothing to tell us that Asta has damage to the central nervous system in the blood nowWith blood tests, it is easy, so that the history of neuroflaments begins with many applications. We are already looking at something in the treatment of some cancer, and we are sure that this is only one beginning. We are fortunate enough to play a pioneer role in these studies in Spain, because we are very happy with the work we do We hope that this will help you to avoid disability. During this time, in patients with multiple sclerosis, and a very wide field opens for research in other pathologies. ”
(tagstotranslate) capacity
Story Credit
